界定目标人群以有效测试神经保护药物
本研究分析627例接受血管内治疗的急性缺血性卒中患者,探讨最终梗死体积与出院/第5天NIHSS的关联,并检验不同选择标准能否提高检出的治疗效果。结果显示,最终梗死体积与5天NIHSS呈二次函数关系(校正β=1.56,95%CI 1.45-1.67,P<0.001)。结论提示,血管内取栓后预后极佳或梗死体积大的患者可能稀释神经保护药物试验的治疗效果,入院CT灌注有助于按预期药物效应选择合适患者。
要点
- 最终梗死体积与5天NIHSS呈二次函数关联,校正β=1.56(95%CI 1.45-1.67,P<0.001)。
- 固定绝对梗死体积减少(5/15 mL)时,排除预测梗死体积较大的患者治疗效果最高。
- 33%相对梗死体积减少模型中,排除预期预后极佳的患者可提高治疗效果。
核心结论
- 血管内取栓后预后极佳或梗死体积大的患者可能稀释卒中神经保护药物试验的治疗效果。
- 入院CT灌注可能有助于根据预期药物效应选择合适患者。
研究设计与样本
- 分析627例接受血管内治疗的急性缺血性卒中患者,最终梗死体积在24-72小时CT上测量。
- 关联模型校正年龄、性别和受累半球,并按基线CT灌注标准划分不同患者亚组。
主要发现
- 最终梗死体积与5天NIHSS的关联以二次函数描述最佳,校正分析回归系数β=1.56(95%CI 1.45-1.67,P<0.001)。
- 固定绝对梗死体积减少(5/15 mL)模型中,排除预测梗死体积较大的患者时治疗效果最高。
- 33%梗死体积减少模型中,排除预期预后极佳的患者时治疗效果增加。
关键数值与推荐
- 最终梗死体积与5天NIHSS关联的校正回归系数β=1.56(95%CI 1.45-1.67,P<0.001)。
- 绝对梗死体积减少分析采用5 mL和15 mL两个固定值。
- 相对梗死体积减少分析采用33%的减少比例。
临床怎么用
- 神经保护药物试验设计时可考虑排除预期预后极佳或梗死体积大的患者以减少效应稀释。
- 入院CT灌注可作为按预期药物效应选择患者的参考工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aim to identify the subgroup of acute ischemic stroke patients with higher probabilities of benefiting from a potential neuroprotective drug using baseline outcome predictors and test whether different selection criteria strategies can improve detected treatment effect. METHODS: We analyzed the association between final infarct volume (FIV), measured on 24- to 72-hour computed tomography, and National Institutes of Health Stroke Scale at discharge/day 5 of acute stroke patients who underwent endovascular treatment. Models were adjusted for age, sex, and affected hemisphere. We analyzed the impact of absolute (5-15 mL) and relative (33%) FIV reductions in the National Institutes of Health Stroke Scale in the whole population and in different subsets of patients selected according to baseline imaging criteria using computed tomography perfusion. RESULTS: We analyzed 627 patients; association between FIV and 5-day National Institutes of Health Stroke Scale was best described with a quadratic function, with a regression coefficient β=1.56 ([95% CI, 1.45-1.67] P<0.001) in the adjusted analysis. In the models considering a fixed absolute (5/15 mL) FIV reduction, treatment effect was highest when patients with predicted larger FIV were excluded, whereas in a 33% FIV reduction model, treatment effect increased with the exclusion of patients with expected excellent outcomes. CONCLUSIONS: Patients either with excellent outcomes after endovascular thrombectomy or with large infarcts may dilute the treatment effect in stroke neuroprotective drug trials. Computed tomography perfusion on admission may help selecting adequate patients according to expected drug effect profile.
引用
- Olivé-Gadea M, Requena M, Campos D, et al. Defining a Target Population to Effectively Test a Neuroprotective Drug. Stroke. 2021. PMID: 33423513. doi:10.1161/STROKEAHA.120.032025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。